MX2017013687A - Polipeptidos dirigidos a la fusion de vih. - Google Patents
Polipeptidos dirigidos a la fusion de vih.Info
- Publication number
- MX2017013687A MX2017013687A MX2017013687A MX2017013687A MX2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A
- Authority
- MX
- Mexico
- Prior art keywords
- hiv fusion
- polypeptides
- targeting hiv
- polypeptides targeting
- fibronectin
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 230000004927 fusion Effects 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 230000008685 targeting Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 108010067306 Fibronectins Proteins 0.000 abstract 2
- 102000016359 Fibronectins Human genes 0.000 abstract 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562152271P | 2015-04-24 | 2015-04-24 | |
| US201562257474P | 2015-11-19 | 2015-11-19 | |
| PCT/US2016/027424 WO2016171980A1 (en) | 2015-04-24 | 2016-04-14 | Polypeptides targeting hiv fusion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013687A true MX2017013687A (es) | 2018-07-06 |
Family
ID=55809237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013687A MX2017013687A (es) | 2015-04-24 | 2016-04-14 | Polipeptidos dirigidos a la fusion de vih. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10407490B2 (enExample) |
| EP (2) | EP3286212B1 (enExample) |
| JP (3) | JP6894846B2 (enExample) |
| KR (1) | KR20170138558A (enExample) |
| CN (1) | CN107922474A (enExample) |
| AU (2) | AU2016252008B2 (enExample) |
| BR (1) | BR112017022790A2 (enExample) |
| CA (1) | CA2983276A1 (enExample) |
| CL (1) | CL2017002687A1 (enExample) |
| CO (1) | CO2017011583A2 (enExample) |
| CR (1) | CR20170482A (enExample) |
| DO (1) | DOP2017000246A (enExample) |
| EA (1) | EA035332B1 (enExample) |
| ES (1) | ES2884267T3 (enExample) |
| HK (1) | HK1243432A1 (enExample) |
| IL (1) | IL255122A0 (enExample) |
| MA (2) | MA56222A (enExample) |
| MX (1) | MX2017013687A (enExample) |
| PE (1) | PE20180162A1 (enExample) |
| PH (1) | PH12017501914A1 (enExample) |
| PT (1) | PT3286212T (enExample) |
| SG (1) | SG11201708441RA (enExample) |
| TW (1) | TW201643185A (enExample) |
| UY (1) | UY36650A (enExample) |
| WO (1) | WO2016171980A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106755100A (zh) * | 2017-02-20 | 2017-05-31 | 李因传 | 可控性hiv‑1基因组靶向编辑系统和其靶向载运系统 |
| US20240239877A1 (en) * | 2017-12-18 | 2024-07-18 | Viiv Healthcare Uk (No. 5) Limited | Antigen binding polypeptides |
| CN108997482B (zh) * | 2018-08-09 | 2025-09-09 | 东莞市朋志生物科技有限公司 | 用于检测hiv-1的合成肽 |
| WO2021081515A2 (en) * | 2019-10-25 | 2021-04-29 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of human immunodeficiency virus |
| CA3230492A1 (en) * | 2021-08-30 | 2023-03-09 | Kanglin Biotechnology (Hangzhou) Co., Ltd. | Gene sequence construct for gene therapy for hiv infection |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| ATE332368T1 (de) | 1997-01-21 | 2006-07-15 | Gen Hospital Corp | Selektion von proteinen mittels rns-protein fusionen |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU2265701A (en) * | 1999-12-16 | 2001-06-25 | Tanox, Inc. | Anti-hiv-1 conjugates for treatment of hiv disease |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| AU2001277867B2 (en) | 2000-07-11 | 2006-12-07 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| AU2003299085B2 (en) * | 2002-09-27 | 2008-04-10 | Tanox, Inc. | Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
| EP1900753B1 (en) | 2002-11-08 | 2017-08-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
| HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CL2008002092A1 (es) | 2007-07-20 | 2009-05-29 | Hoffmann La Roche | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. |
| WO2009083804A2 (en) | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
| EA201001734A1 (ru) | 2008-05-02 | 2011-10-31 | Новартис Аг | Улучшенные связывающие молекулы на основе фибронектина и их применение |
| ES2705714T3 (es) | 2008-10-31 | 2019-03-26 | Janssen Biotech Inc | Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones |
| GB0920944D0 (en) * | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
| WO2011077093A1 (en) * | 2009-12-22 | 2011-06-30 | Aarhus Universitet | Bivalent molecules for hiv entry inhibition |
| EP2558491B1 (en) * | 2010-04-13 | 2018-07-04 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind pcsk9 |
| TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| CN102939538A (zh) * | 2010-05-07 | 2013-02-20 | 霍夫曼-拉罗奇有限公司 | 用于离体检测细胞的诊断方法 |
| CN103380143B (zh) | 2010-12-22 | 2016-01-06 | 百时美施贵宝公司 | 结合il-23的基于纤连蛋白的支架结构域蛋白质 |
| WO2012159164A1 (en) | 2011-05-23 | 2012-11-29 | Phylogica Limited | Method of determining, identifying or isolating cell-penetrating peptides |
| JP6440496B2 (ja) | 2011-09-27 | 2018-12-19 | ヤンセン バイオテツク，インコーポレーテツド | 選択的結合表面を有するフィブロネクチンｉｉｉ型反復ベースのタンパク質スカフォールド |
| EP2951206A2 (en) * | 2013-02-01 | 2015-12-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| EP2968587A2 (en) * | 2013-03-13 | 2016-01-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
| CN103333255A (zh) | 2013-06-28 | 2013-10-02 | 复旦大学 | 一种长效hiv‐1膜融合抑制剂 |
-
2016
- 2016-04-14 EA EA201792269A patent/EA035332B1/ru not_active IP Right Cessation
- 2016-04-14 CR CR20170482A patent/CR20170482A/es unknown
- 2016-04-14 AU AU2016252008A patent/AU2016252008B2/en not_active Ceased
- 2016-04-14 EP EP16718817.6A patent/EP3286212B1/en active Active
- 2016-04-14 SG SG11201708441RA patent/SG11201708441RA/en unknown
- 2016-04-14 MA MA056222A patent/MA56222A/fr unknown
- 2016-04-14 MX MX2017013687A patent/MX2017013687A/es unknown
- 2016-04-14 CN CN201680036930.XA patent/CN107922474A/zh active Pending
- 2016-04-14 JP JP2017555557A patent/JP6894846B2/ja not_active Expired - Fee Related
- 2016-04-14 WO PCT/US2016/027424 patent/WO2016171980A1/en not_active Ceased
- 2016-04-14 PT PT167188176T patent/PT3286212T/pt unknown
- 2016-04-14 EP EP21176464.2A patent/EP3985020A1/en not_active Withdrawn
- 2016-04-14 US US15/568,830 patent/US10407490B2/en active Active
- 2016-04-14 PE PE2017002311A patent/PE20180162A1/es unknown
- 2016-04-14 ES ES16718817T patent/ES2884267T3/es active Active
- 2016-04-14 MA MA041943A patent/MA41943A/fr unknown
- 2016-04-14 HK HK18102882.7A patent/HK1243432A1/zh unknown
- 2016-04-14 KR KR1020177033985A patent/KR20170138558A/ko not_active Withdrawn
- 2016-04-14 CA CA2983276A patent/CA2983276A1/en not_active Abandoned
- 2016-04-14 BR BR112017022790-8A patent/BR112017022790A2/pt not_active IP Right Cessation
- 2016-04-22 UY UY0001036650A patent/UY36650A/es not_active Application Discontinuation
- 2016-04-22 TW TW105112708A patent/TW201643185A/zh unknown
-
2017
- 2017-10-18 IL IL255122A patent/IL255122A0/en unknown
- 2017-10-19 PH PH12017501914A patent/PH12017501914A1/en unknown
- 2017-10-23 DO DO2017000246A patent/DOP2017000246A/es unknown
- 2017-10-23 CL CL2017002687A patent/CL2017002687A1/es unknown
- 2017-11-14 CO CONC2017/0011583A patent/CO2017011583A2/es unknown
-
2019
- 2019-08-07 US US16/533,941 patent/US11155602B2/en active Active
- 2019-09-06 AU AU2019226255A patent/AU2019226255A1/en not_active Abandoned
-
2020
- 2020-10-16 JP JP2020174288A patent/JP2021035951A/ja active Pending
-
2023
- 2023-02-03 JP JP2023014947A patent/JP7465378B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501914A1 (en) | Polypeptides targeting hiv fusion | |
| CY1124756T1 (el) | Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας | |
| PH12018500873A1 (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection | |
| PH12021500001A1 (en) | Antibodies that target hiv gp120 and methods of use | |
| GB2578802B8 (en) | Programmable DNA binding proteins that increase efficiency and/or specificity of genome targeting in eukaryotic cells for use in therapy | |
| MX2021003475A (es) | Metodos de purificacion de proteinas. | |
| WO2015109124A3 (en) | Immunomodulatory agents | |
| BR112016020377A2 (pt) | proteínas fc multiméricas | |
| MX2018000590A (es) | Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79). | |
| CL2008002092A1 (es) | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. | |
| MX2019014504A (es) | Inmunoglobulinas de union a agrecano. | |
| MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. | |
| MX2017001038A (es) | Variantes de proteina de unión al factor h y metodos de uso de estas. | |
| PH12018500159A1 (en) | Constructs targeting psa peptide/mhc complexes and uses thereof | |
| CY1125014T1 (el) | Υποκατεστημενα παραγωγα ξανθινης | |
| MX2019003970A (es) | Péptidos de arginasa inmunogénicos. | |
| NZ731491A (en) | Cd83 binding proteins and uses thereof | |
| PH12018500645A1 (en) | Hiv antibody compositions and methods of use | |
| MX374177B (es) | Farmaco antirretroviral dirigido a un retrovirus endogeno humano. | |
| WO2018222991A3 (en) | PAC1 ANTAGONIST PEPTIDES | |
| WO2020117740A8 (en) | Recombinant hiv env polypeptides and their uses | |
| AR104390A1 (es) | Polipéptidos dirigidos a la fusión de vih | |
| MX385558B (es) | Péptidos y métodos de uso. | |
| EA201991733A1 (ru) | Фармацевтические композиции для комбинированной терапии | |
| EA201992151A1 (ru) | Фармацевтические композиции для комбинированной терапии |